PVLA - NASDAQ

Palvella Therapeutics, Inc.

PVLA·NASDAQ

$115.42

+10%

HealthcareBiotechnology

Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. Its lead product candidate is QTORIN 3.9% rapamycin anhydrous gel (QTORIN rapamycin) that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations. It also develops QTORIN rapamycin for the treatment of other mTOR-driven skin diseases. The company is based in Wayne, Pennsylvania.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$1.37B

EPS-3.7100

P/E Ratio-31.11

Earnings Date08/13/2026

pvla

Accumulated Other Comprehensive Income (Loss)

Last Annual Value

83.00K

3-Year CAGR

5-Year CAGR

18%

10-Year CAGR

Adjust for Inflation

Palvella Therapeutics, Inc. Competitors Analysis of Accumulated Other Comprehensive Income (Loss)

PVLA · NASDAQ

Company	Accumulated Other Comprehensive Income (Loss)	CAGR 3Y	CAGR 5Y	CAGR 10Y
Palvella Therapeutics, Inc. NASDAQ:PVLA	83.00K	N/A	-36.9%	N/A
Tyra Biosciences, Inc. NASDAQ:TYRA	393.00K	1.0%	N/A	N/A
ProKidney Corp. NASDAQ:PROK	56.00K	-24.5%	N/A	N/A
Kura Oncology, Inc. NASDAQ:KURA	1.02M	N/A	N/A	N/A
Savara Inc. NASDAQ:SVRA	-87.00K	N/A	N/A	N/A
Rezolute, Inc. NASDAQ:RZLT	-7.00K	N/A	N/A	N/A
ARS Pharmaceuticals, Inc. NASDAQ:SPRY	125.00K	36.6%	N/A	N/A
Arbutus Biopharma Corporation NASDAQ:ABUS	-48.10M	N/A	N/A	N/A
EyePoint Pharmaceuticals, Inc. NASDAQ:EYPT	961.00K	3.6%	2.7%	1.2%

Palvella Therapeutics, Inc. Fair Value Envelope

PVLA · NASDAQ

Our analysis suggests that PVLA has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $115.42, this represents a potential HIDDEN relative to our calculated worth for Palvella Therapeutics, Inc..

HIDDEN

Intrinsic Value

Current Price: $115.42

Related Guides

Blog Categories

Continue your PVLA research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.